China’s biotechnology sector is undergoing a profound transformation, evolving from rapid expansion into a new phase defined by quality, global relevance, and sustained innovation. What was once an emerging segment is now a core pillar of China’s high-value technology economy, with measurable progress across drug discovery, clinical development, regulatory advancement, and international collaboration.
According to the latest Clarivate report, Mainland China Biopharma Innovation 2.0: From Rapid Growth to Quality-Driven Development, China became the world’s second-largest source of first launches of new molecular entities (NMEs) in 2024, accounting for 18 percent of the global total. The findings mark a significant milestone in China’s transition from Innovation 1.0—characterized by scale and speed—into Innovation 2.0, where consistency, scientific rigor, and global recognition take center stage.
This shift is also evident in clinical development. A joint report by L.E.K. Consulting and PharmaDJ shows that China’s clinical trial volume has expanded rapidly, reaching levels comparable with leading global markets in 2024. The growth reflects not only capacity expansion but also rising confidence in China’s clinical infrastructure, regulatory efficiency, and data quality.
Regulatory progress further reinforces this momentum. Analysis from the Clarivate Centre for Innovation in Regulatory Science (CIRS) indicates that between 2019 and 2023, a majority of new active substances approved by major global regulators were also approved in China or remain under active review by the National Medical Products Administration (NMPA). Notably, several Class 1 innovative chemical drugs were submitted in China before receiving first global approval, signaling that China is increasingly being integrated earlier into global development and commercialization strategies.
China’s expanding role is also reflected in transaction activity. By 2025, China-origin biopharmaceutical deal volume surpassed 8 percent of global totals. From January through August 2025 alone, out-licensing activity matched the entirety of 2024, with transaction values reaching approximately US$50 billion. Both deal volume and value had already exceeded the previous year well before year-end, highlighting the growing commercial confidence in China-based innovation.
Therapeutic focus areas within China’s biotech ecosystem are also becoming more sophisticated. While interest in certain antibody-drug conjugate targets moderated between 2024 and 2025, attention shifted toward bispecific and multispecific antibodies, as well as next-generation small-molecule therapeutics. Targets such as PD-(L)1 × VEGF and GLP-1 receptors have seen rising activity, underscoring China’s ability to move in step with evolving scientific frontiers. High-value global licensing agreements originating from China further demonstrate the international relevance of these innovations.
Equally important is the growing credibility of China-generated clinical data. An increasing number of China-origin medicines are receiving global regulatory recognitions and being presented at major international medical conferences. This trend reflects improved trial design, stronger compliance with international standards, and deeper integration of China’s research outputs into global medical discourse.
At the company level, sustained investment in research and development continues to underpin this progress. In 2024, median R&D intensity among China’s top 20 biotech innovators reached 22 percent, with an average of 28 percent. These figures align closely with national policy goals outlined in China’s 14th Five-Year Plan for the Pharmaceutical Industry, which emphasizes double-digit annual R&D growth and a minimum R&D intensity of 10 percent among leading enterprises. The result is a virtuous cycle in which policy support, private investment, and scientific talent reinforce one another.
China’s biotech rise is also delivering broader economic and technological benefits. The sector is driving high-quality employment, strengthening advanced manufacturing capabilities, and accelerating the commercialization of frontier technologies. Government support, large-scale infrastructure investment, and a deep talent pool have helped create a dense innovation ecosystem spanning academia, startups, contract research organizations, and global partners.
As industry observers note, China’s execution efficiency, development speed, and cost advantages have positioned it as an indispensable source of innovation within the global life sciences ecosystem. While challenges remain—particularly around pricing dynamics and market competition—the overall trajectory points toward a more mature, resilient, and globally influential biotech industry.
Looking ahead, China’s continued emphasis on basic research, intellectual property protection, and regulatory modernization will shape the next phase of development. With sustained investment and policy alignment, the biotech sector is poised to remain a strategic engine of growth—supporting China’s ambitions in advanced healthcare, technological self-reliance, and long-term economic upgrading.